Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
EVO Evotec
9.970+0.040+0.40%
Close
02/07 16:00 ET
9.9700.0000.00%
Post Mkt Price 02/07 18:40 ET
High
10.075
Open
9.860
Turnover
129.87K
Low
9.780
Pre Close
9.930
Volume
13.19K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Evotec SE Gets New Finance Chief
German Biotech Evotec Names New CFO
02:45 AM EST, 02/07/2023 (MT Newswires) -- Evotec (EVT.F) said Tuesday that its board has appointed Laetitia Rouxel as the new chief financial officer, effective April 1. Rouxel will succeed Enno Spil
Evotec SE Named Industry Veteran Laetitia Rouxel as CFO Effective April 1; Former Finance Chief Enno Spillner Will Depart To Pursue Other Opportunities
Evotec SE ((Frankfurt Stock Exchange: EVT, MDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO) announced today that the Company's Supervisory Board has appointed Laetitia Rouxel as new Chief Financial Officer and mem
Evotec SE: Laetitia Rouxel to Succeed Enno Spillner as Chief Financial Officer
HAMBURG, GERMANY / ACCESSWIRE / February 7, 2023 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) announced today that the Company's Supervisory Board has appoi
Evotec SE Appoints Laetitia Rouxel As CFO
Evotec (OTCMKTS:EVTCY) Reaches New 12-Month Low at $9.81
Evotec SE (OTCMKTS:EVTCY – Get Rating)'s share price hit a new 52-week low during mid-day trading on Monday . The stock traded as low as $9.81 and last traded at $9.85, with a volume of 6946 shares.
Analysts Conflicted on These Healthcare Names: Can-Fite BioPharma (CANF), CareDx (CDNA) and Evotec AG (EVO)
Evotec Price Target Maintained With a $12.00/Share by HC Wainwright & Co.
Evotec Price Target Maintained With a $12.00/Share by HC Wainwright & Co.
Evotec Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 01/27/2023 16.05% HC Wainwright & Co. → $12 Reiterates → Buy 12/09/2022 16.05% HC Wainwright & Co. → $12 I
HC Wainwright & Co. Reiterates Buy on Evotec, Maintains $12 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Evotec with a Buy and maintains $12 price target.
Company Overview
More
Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.
CEO： Dr. Werner Lanthaler, PhD
Market： NASDAQ
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet